Labetalol is contraindicated in people with asthma. The FDA labels for both oral and injectable forms list bronchial asthma as an absolute contraindication, not a relative one. This means it should not be given to asthmatic patients regardless of how well-controlled their asthma appears to be.
Why Labetalol Is Dangerous for Asthma
Labetalol blocks two types of receptors in the body: alpha-1 receptors (which affect blood vessels) and beta receptors (which affect the heart and lungs). The problem is that it blocks beta receptors non-selectively, meaning it hits both the beta-1 receptors in the heart and the beta-2 receptors in the airways. Beta-2 receptors are what keep your airways relaxed and open. When those receptors are blocked, the smooth muscle around your airways can tighten, triggering bronchospasm.
Making matters worse, labetalol directly counteracts rescue inhalers. Medications like albuterol work by activating beta-2 receptors to open the airways. Labetalol blocks those same receptors, so if bronchospasm occurs, your rescue inhaler becomes significantly less effective. In a meta-analysis of people with asthma, rescue inhaler response (measured by lung function improvement) dropped from a 23% increase with placebo to just a 1% decline after a non-selective beta-blocker. That’s not just reduced effectiveness; it’s a near-total loss of your main emergency tool.
Labetalol is actually more potent at blocking beta receptors than alpha receptors. The ratio is 3:1 (beta to alpha) when taken orally and nearly 7:1 when given intravenously. So while it’s sometimes described as a “combined” blocker, the beta-blocking effect dominates, especially by IV.
How Serious Is the Risk?
Non-selective beta-blockers have caused fatal bronchospasm in people with asthma. At least six separate case reports document severe or fatal airway reactions in asthmatics given non-selective beta-blockers. Some of those cases involved only eye drops containing a beta-blocker, not even an oral or IV dose. Labetalol falls into this non-selective category.
Even a single dose of a non-selective beta-blocker can reduce baseline lung function by about 10% in asthmatic patients. That may not sound dramatic, but for someone whose airways are already prone to constriction, a 10% drop can push them into a clinically dangerous episode. The signs of beta-blocker-induced bronchospasm include wheezing, chest tightness, coughing, shortness of breath, and the feeling of not being able to catch your breath.
Labetalol and Pregnancy With Asthma
This question comes up frequently in pregnancy because labetalol is one of the most commonly prescribed blood pressure medications for pregnant women. The American College of Obstetricians and Gynecologists (ACOG) recommends labetalol or nifedipine as first-line options for chronic hypertension in pregnancy. However, ACOG explicitly states that labetalol should be avoided in women with asthma, both for long-term blood pressure management and for urgent blood pressure control during pregnancy.
If you’re pregnant with both high blood pressure and asthma, nifedipine is the typical alternative. It’s a calcium channel blocker that lowers blood pressure without affecting the airways at all. Your provider can choose from this and other non-beta-blocker options to manage blood pressure safely.
Safer Alternatives if You Have Asthma
If you genuinely need a beta-blocker for a heart condition, highly selective beta-1 blockers like bisoprolol are considered the safest option. These drugs preferentially block beta-1 receptors in the heart while leaving beta-2 receptors in the lungs relatively untouched. No published reports have documented fatal or severe bronchospasm from cardioselective beta-1 blockers in people with asthma.
That said, “selective” doesn’t mean “zero risk.” Even cardioselective beta-blockers reduced lung function by about 7% in asthmatic patients after a single dose, and they blunted rescue inhaler response from a 23% improvement down to 16%. The risk is meaningfully lower than with non-selective agents, but it still exists. Bisoprolol at the lowest effective dose is the approach most likely to minimize airway problems when a beta-blocker is truly needed.
For blood pressure management alone, several drug classes avoid beta receptors entirely. Calcium channel blockers, ACE inhibitors, and angiotensin receptor blockers all lower blood pressure without touching the airways. These are typically preferred over any beta-blocker in people with asthma unless there’s a specific cardiac reason (like heart failure or a heart rhythm problem) that makes a beta-blocker necessary.